Karyopharm Therapeutics (NASDAQ: KPTI) has announced enrollment completion in its Phase 3 SENTRY trial, designed to evaluate selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis (MF) patients. According...
Greenwich LifeSciences (NASDAQ: GLSI) announced that the FDA has granted GLSI-100 fast track designation for the treatment of patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed treatment...
MedX Health (TSXV: MDX) has announced the appointment of Dr. Paul J. Matts, internationally recognized skin scientist, biochemist, and educator, as strategic advisor. Dr. Matts is an academic and industry leader, as...
Closely held Micoy Therapeutics is advancing novel, first-in-class therapeutics to target harmful autoantibodies that induce immunodeficiency by inhibiting immune signaling molecules—type I interferons—which are...
Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX: PYNKF) announced that it has joined the American Society of Breast Surgeons (ASBrS) Industry Relations Council (IRC). The ASBrS is the primary leadership organization for...
Insight Molecular Diagnostics (iMDX) (NASDAQ: IMDX) has announced a positive strategic update and novel registry to gather real-world data on patient experiences and outcomes concerning its flagship kidney transplant...
Evolus (NASDAQ: EOLS) has announced the appointment of Tatjana Mitchell as chief financial officer (CFO), effective today. Ms. Mitchell brings more than 20 years of strategic and operational finance leadership across...
Pasithea Therapeutics (NASDAQ: KTTA) announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004...
Firefly Neuroscience (NASDAQ: AIFF) announced a new partnership with HealingMaps the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (TMS) clinics, and Advanced...
Palisade Bio (NASDAQ: PALI) has announced receiving a No Objection Letter (NOL) from Health Canada for its clinical trial application to evaluate PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor, in...